



## **ANNOUNCEMENT NO. 202**

March 18<sup>th</sup>, 2021

### **Revenue and EBITDA guidance raised**

ChemoMetec has continued its positive development into the second half of the financial year 2020/21, where sales developed better than expected especially in the European market.

As a result of the higher revenue and the continued low sales-related expenses due to the COVID-19 restrictions, ChemoMetec is raising its guidance for both revenue and EBITDA for the 2020/21 financial year.

ChemoMetec now expects revenue in the DKK 263-268 million range, up from DKK 250-260 million, and EBITDA in the DKK 120-125 million range, up from DKK 110-115 million.

Due to the COVID-19 situation, the outlook is subject to greater uncertainty than usual in part because the current restrictions are affecting ChemoMetec's ability to visit customers.

ChemoMetec expects to release its Q3 2020/21 trading statement (1 January to 31 March 2021) on Thursday, 6 May 2021.

### **For further information, please contact**

Steen Søndergaard, CEO, ChemoMetec A/S

Tel.: (+45) 4813 1020

### **About ChemoMetec A/S**

*ChemoMetec develops, manufactures and markets analytical instruments for cell counting and a wide range of other measurements. ChemoMetec's analytical instruments are marketed to the pharmaceutical industry, biotech and agriculture worldwide. ChemoMetec's customers comprise some of the world's leading pharmaceutical companies, including Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.*

*ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For more information, go to [www.chemometec.com](http://www.chemometec.com).*